News

The NDA submission follows a pre-NDA meeting with the FDA and the recently announced results from the phase 3 trial of Axiron. The trial demonstrated that after four

Eddie Catalfamo, president and CEO of Santica Research Labs, said: “This unique supplement, made from carefully selected natural botanical extracts, targets the underlying factors that contribute to the

Cenestra said that scientific data obtained from third party academic laboratories support its proprietary formulation as having novel properties compared to other omega-3 products. These studies show that

Through the deal, American Medical Systems has a four year option to obtain distribution and license rights to Tissue Genesis’ regenerative cell technology including the Tissue Genesis Cell

Fourth quarter 2009 sales posted by the company were $1.64 billion, compared to fourth quarter 2008 sales of $1.60 billion. Sales increased 2% as favorable foreign currency exchange

Under the settlement and cross-license agreement, Bavarian Nordic will grant a license to its MVA-BN patents, in return for Oxford BioMedica granting a license to its heterologous prime-boost

During the test period, Shionogi was able to compare HuCAL Platinum with its predecessor HuCAL Gold, and found the new library to be considerably better. As per the

First Response has patent pending technology that can detect the pregnancy hormone, human chorionic gonadotropin (hCG), up to six days before the day of a woman’s missed period,

The safety and efficacy of Berinert for prophylactic therapy has not been established. Berinert is now available through specialty pharmacies and distributors in the US. Robert Lefebvre, vice